Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PTC Therapeutics ( (PTCT) ) just unveiled an announcement.
On Feb. 19, 2026, PTC Therapeutics reported that full-year 2025 product and royalty revenue reached $831 million, exceeding guidance, driven by the successful global launch of Sephience, which generated $111 million since its second-half 2025 debut and contributed to total 2025 revenues of $1.73 billion. The company strengthened its balance sheet to $1.95 billion in cash by year-end, boosted by a $998.4 million Novartis collaboration on votoplam and the sale of remaining Evrysdi royalties, while advancing its pipeline with FDA alignment on a Phase 3 Huntington’s trial and receiving feedback that an additional study is needed to resubmit vatiquinone in Friedreich’s ataxia, as it guides investors with 2026 product revenue expectations of $700 million to $800 million and higher R&D and SG&A spending.
The most recent analyst rating on (PTCT) stock is a Buy with a $124.00 price target. To see the full list of analyst forecasts on PTC Therapeutics stock, see the PTCT Stock Forecast page.
Spark’s Take on PTCT Stock
According to Spark, TipRanks’ AI Analyst, PTCT is a Outperform.
The score is led by strong recent operating performance and cash generation, plus positive commercial traction and guidance around Sephience. It’s held back primarily by balance-sheet leverage/negative equity and some execution risks (payer timelines, Emflaza uncertainty), while technicals and a low P/E provide additional support.
To see Spark’s full report on PTCT stock, click here.
More about PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and serious disorders, including genetic and neurological diseases. Its portfolio includes products such as Translarna, Emflaza, Evrysdi royalties and the recently launched Sephience, with a growing global footprint across major markets including the U.S., Japan, Brazil and additional countries expected by 2026.
Average Trading Volume: 1,567,506
Technical Sentiment Signal: Buy
Current Market Cap: $5.55B
See more data about PTCT stock on TipRanks’ Stock Analysis page.